Shared decision making between patients with Fabry disease and physicians in Japan: An online survey.

"Declaration of Competing Interest Natsuko Inagaki has no conflict of interest to disclose. Takeo Nakayama received grants or contracts from I&H Co., Ltd. and Nakagawa Pharmacy Co., consulting fees from Otsuka Pharmaceutical Co., Ltd., and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Baxter Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., and Allergan Japan K.K. Kazuki Otani and Mio Tsuchiya are full-time employees of Amicus Therapeutics K.K., Japan."

"The authors wish to thank the patients and physicians who participated in this survey, and Mebix for providing support for protocol development and statistical analysis as the CRO which was funded by Amicus Therapeutics K.K., Japan, the authors also thank Keyra Martinez Dunn, MD, of Edanz (www.edanz.com) for providing medical writing support, which was funded by Amicus Therapeutics K.K., Japan, in accordance with Good Publication Practice guidelines (http://www.ismpp.org/gpp3)."